



MedImmune

CALL FOR ABSTRACTS IN ONCOLOGY

MedImmune's Oncology Research Department invites authors to submit abstracts which describe their scientific work in the field of tumor microenvironment for consideration in the MedImmune Oncology Research Abstract Competition. Qualified applicants include graduate students and postdoctoral fellows in Europe. Abstracts will be reviewed by a panel of experts and selected for awards on the basis of scientific merit.

Authors of the top ten abstracts will be invited to present at MedImmune's research facility in Cambridge, U.K., with travel expenses (including two nights' accommodation) covered by MedImmune. Three winners will be selected based on presentation content and delivery, with cash awards of £2,000, £1,000, and £500 issued to the first, second, and third place awardees.

The deadline for abstract submission is **October 8, 2010**. Please submit via email to abstractoncology@medimmune.com. Notification of acceptance or rejection by the scientific committee will be mailed on October 15, 2010. Abstract presentations will take place on November 3, 2010.

Guidelines for the preparation of abstracts

- Maximum one page with size 12 font
- A title (in capital letters) that clearly indicates the nature of the investigation
- Abbreviations should be avoided in the titles, but may be used in the text if they are defined on the first usage
- The author's full name and place of work (institution, city, country)
- The abstract should be as informative as possible
 - State the specific objective of study
 - State the methods used, if pertinent
 - Summarise the results obtained
 - State the conclusions reached

The reviewers will judge the abstracts according to objectivity of statement, description of what was done, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall impression.

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

This competition is not open to medical professionals who prescribe, supply or administer medicines or to anyone who recommends, buys or sells medicines.

ADVANCING SCIENCE FOR BETTER HEALTH

www.medimmune.com